Dianthus Therapeutics Net Income

The latest net income for DNTH is $-30M as of June 2026. That compares with $-110M in the prior-year period — up 73.9% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside Dianthus Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, DNTH's net income moved from $-110M to $-30M — a 73.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dianthus Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, DNTH currently prints $-30M for net income, while the sector average sits near $17B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Dianthus Therapeutics's growth, margins, and balance sheet.

A net income figure of $-30M for DNTH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.

After noting DNTH's net income ($-30M), review year-over-year change from $-110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.